High Protein Costs and Search Ranking Changes Weigh on FitLife Brands (FTLF) in Q3

Alluvial Fund's Q3 2026 investor letter highlights FitLife Brands (FTLF) struggles due to high protein costs and Amazon ranking changes, despite a 12% EBITDA rise. Shares fell 5.98% in the past month, with a 52-week loss of 56.37%. The company's market cap is $76.82M, trading at less than 10x normalized earnings.

Original reporting
Published Nov 5, 2026, 3:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
High Protein Costs and Search Ranking Changes Weigh on FitLife Brands (FTLF) in Q3 — source image
Decision brief

The 30-second read

$FTLFBearishLow
01

Why it matters

FitLife’s share price has already slipped; the fund’s negative outlook may accelerate selling.

02

Market read

The commentary adds a bearish perspective on a micro‑cap nutrition company, offering a modest trading signal for short‑term traders.

03

What to watch

Potential upside from Irwin Naturals integration and cash generation could mitigate short-term pressure.

Relevance 4/10Novelty 3/10Timing: post-market today

Background

Alluvial Capital Management’s Q3 fund letter comments on FitLife Brands’ operational challenges amid high protein input costs and Amazon algorithm changes.

Company-level read

Ticker impact

$FTLFBearishMedium confidence
Context

Alluvial Fund letter highlights FitLife Brands facing high protein costs and Amazon ranking drops, noting a 5.98% price decline and margin pressure.

Expected impact

downward pressure as margins compress and tax-loss selling intensifies

Evidence & confidence

Fund commentary flags margin squeeze and potential tax-loss selling, both bearish catalysts.

Market effects

Protein supplement sector may see broader margin pressure if whey prices stay high.

U.S. consumer discretionary stocks could feel slight drag from cost inflation.

Limited; primarily affects niche nutrition supplement players.

Counterpoint

If FitLife can secure lower protein input costs or improve Amazon SEO, the stock may rebound.

Key entities

  • FitLife Brands, Inc.

    Provider of nutritional supplements and wellness products (NASDAQ:FTLF).

  • Alluvial Capital Management

    Manager of the Alluvial Fund, which disclosed the commentary.

Related articles

$FTLFMed

FitLife Brands (FTLF) Q2 2026 Earnings Call Transcript

FitLife Brands (FTLF) reported Q2 2026 earnings. Legacy FitLife's gross margin rose to 41.7%, but contribution fell 25.9% to $4.2M. Irwin's revenue hit $14.1M, with Amazon sales growing. The company is improving supply chain, product development, and marketing. SG&A costs dropped 3.8% sequentially. The term loan balance is $36.1M, with $8.6M of debt paid since the Irwin acquisition.

$FTLFMed

FitLife Brands Q2 Earnings Call Highlights

FitLife Brands (NASDAQ:FTLF) reported Q2 call highlights. Irwin direct Amazon sales rose from about $500k monthly in Dec 2025 to about $1m in June 2026, with July comparable to June. Legacy revenue fell 23% YoY to $12.4m; gross margin 41.7%. FitLife is extending Irwin shelf life and launching new products. It paid about $1.5m term-loan, cutting term-loan to $36.1m.

$FTLFMed

FitLife Brands Announces Second Quarter 2026 Results

FITLIFE BRANDS, INC. (FTLF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FitLife Brands Announces Second Quarter 2026 Results OMAHA, NE – August 13, 2026 – FitLife Brands, Inc. (“ FitLife ” or the “ Company ”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$UALMed

United Airlines system outage disrupts departures, 418 flights delayed

United Airlines experienced a system outage causing 418 flight delays. The issue affected departing flights and pilot applications, but not in-air flights or United Express services. The airline resolved the outage, attributing it to a technology issue, not cybersecurity. Recent U.S. tech disruptions include JPMorgan Chase's banking service delays and an FAA air traffic control system malfunction.

$BAMed

First permanently assigned F-15EXs touch down at Kadena Air Base

Kadena Air Base in Japan received two permanently assigned F-15EX Eagle II fighter jets, marking the first overseas U.S. base to do so. The Air Force aims to boost airpower in the Pacific, replacing older F-15C/D models. The jets, with advanced avionics and weapons capacity, will support operations with Japan and regional partners. Boeing received a $2.38 billion contract for 22 more F-15EXs, increasing the total to 120.